Avalon GloboCare Corp. (NASDAQ:CHGA) Shares Shorted: Short Interest Down 51.8% in September

Avalon GloboCare Corp. (NASDAQ:CHGA) saw a significant drop in short interest during the month of September. As of September 15th, there was short interest totaling 33,188 shares, a drop of 51.8% from the August 31st total of 68,808 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average trading volume of 48,548 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Avalon GloboCare Stock Down 3.0%

NASDAQ:CHGA traded down $0.06 during mid-day trading on Tuesday, hitting $1.92. 21,002 shares of the stock traded hands, compared to its average volume of 198,308. The company has a market cap of $2.15 million, a PE ratio of -0.14 and a beta of -0.05. Avalon GloboCare has a 12-month low of $1.79 and a 12-month high of $49.20. The business’s 50-day moving average price is $3.98 and its 200 day moving average price is $6.59.

Avalon GloboCare (NASDAQ:CHGA) last issued its quarterly earnings data on Friday, August 14th. The company reported ($2.80) earnings per share (EPS) for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp. is a life sciences company focused on developing cell-based technologies and precision medicine applications. Its work has included regenerative medicine, cancer diagnostics, and therapeutic platforms designed to support the development of personalized healthcare treatments.

The company has also pursued technologies involving cellular processing, biomanufacturing, and related laboratory services. Avalon GloboCare’s activities have included collaborations and development programs intended to translate emerging cell and molecular science into clinical and commercial applications.

Avalon GloboCare was established in the mid-2010s and has been headquartered in Freehold, New Jersey.